• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SUGT1是一种预后生物标志物,与卵巢癌中的免疫浸润相关。

SUGT1 is a prognostic biomarker and is associated with immune infiltrates in ovarian cancer.

作者信息

Ge Linyan, Liu Xiu, Zhang Lingyan, Zhang Jiaren, Song Guanghui

机构信息

Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, NO. 3 Qingchun East Road, Hangzhou, 310016, China.

Key Laboratory of Reproductive Dysfunction Management of Zhejiang Province, School of Medicine, Zhejiang University, Hangzhou, China.

出版信息

Eur J Med Res. 2025 Jan 10;30(1):21. doi: 10.1186/s40001-024-02232-5.

DOI:10.1186/s40001-024-02232-5
PMID:39794869
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11724497/
Abstract

BACKGROUND

Ovarian cancer (OC) is a prevalent gynecological malignancy with a relatively dismal prognosis. The SGT1 homolog (SUGT1) protein, which interacts with heat shock protein 90 and is essential for the G1/S and G2/M transitions, was formerly thought to be a cancer promoter, but its precise role in OC remains unknown.

METHODS

We conducted a comprehensive bioinformatics analysis of SUGT1 expression in patients with OC compared with their normal controls, including the data from the cancer genome atlas (TCGA), genotype-tissue expression (GTEx) databases, gene ontology (GO) analysis, Kyoto Encylopedia of Genes and Genomes (KEGG) analysis, gene set enrichment analysis (GSEA), single sample gene set enrichment analysis (ssGSEA). In addition, Kaplan-Meier (KM) analysis, univariate and multivariate Cox analyses were applied to investigate the prognostic role of SUGT1 in ovarian cancer. Furthermore, we validated the expression of SUGT1 in OC and normal tissues through immunohistochemistry.

RESULTS

SUGT1 was significantly overexpressed in OC than in normal tissues. In addition, the GO, KEGG and GSEA analysis revealed that SUGT1 was associated with the functions related to immunoglobulin complex, antigen binding, immunoglobulin receptor binding, among others. Besides, ssGSEA demonstrated a positive correlation between SUGT1 expression and the abundance of T central memory cells, natural killer cells, and T gamma delta cells, although it showed a negative association with activated dendritic cells, cytotoxic cells, T cells, and T helper 1 cells. Subsequently, KM survival analysis revealed that high SUGT1 expression indicated a shorter overall survival, disease specific survival and progression free interval in OC patients. Univariate and multivariate Cox regression revealed that SUGT1 could serve as an independent risk factor for prognosis of patients with OC.

CONCLUSIONS

All these results of this study show that SUGT1 is an important molecular component in immune infiltration in OC and may have a new significant prognostic role in OC.

摘要

背景

卵巢癌(OC)是一种常见的妇科恶性肿瘤,预后相对较差。SGT1同源蛋白(SUGT1)与热休克蛋白90相互作用,对G1/S期和G2/M期转换至关重要,以前被认为是癌症促进因子,但其在OC中的具体作用仍不清楚。

方法

我们对OC患者与正常对照者的SUGT1表达进行了全面的生物信息学分析,包括来自癌症基因组图谱(TCGA)、基因型-组织表达(GTEx)数据库的数据,基因本体(GO)分析、京都基因与基因组百科全书(KEGG)分析、基因集富集分析(GSEA)、单样本基因集富集分析(ssGSEA)。此外,应用Kaplan-Meier(KM)分析、单因素和多因素Cox分析来研究SUGT1在卵巢癌中的预后作用。此外,我们通过免疫组织化学验证了SUGT1在OC和正常组织中的表达。

结果

SUGT1在OC中显著高于正常组织表达。此外,GO、KEGG和GSEA分析显示,SUGT1与免疫球蛋白复合物、抗原结合、免疫球蛋白受体结合等相关功能有关。此外,ssGSEA显示SUGT1表达与T中央记忆细胞、自然杀伤细胞和Tγδ细胞的丰度呈正相关,尽管它与活化树突状细胞、细胞毒性细胞、T细胞和T辅助1细胞呈负相关。随后,KM生存分析显示,高SUGT1表达表明OC患者的总生存期、疾病特异性生存期和无进展生存期较短。单因素和多因素Cox回归显示,SUGT1可作为OC患者预后的独立危险因素。

结论

本研究的所有这些结果表明,SUGT1是OC免疫浸润中的重要分子成分,可能在OC中具有新的重要预后作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f6c/11724497/044a5ae53501/40001_2024_2232_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f6c/11724497/59fe403cdea4/40001_2024_2232_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f6c/11724497/e675e0ecc087/40001_2024_2232_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f6c/11724497/a3ab4d1f3bc1/40001_2024_2232_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f6c/11724497/ca6b1e40ac30/40001_2024_2232_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f6c/11724497/d2ca77a203f2/40001_2024_2232_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f6c/11724497/044a5ae53501/40001_2024_2232_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f6c/11724497/59fe403cdea4/40001_2024_2232_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f6c/11724497/e675e0ecc087/40001_2024_2232_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f6c/11724497/a3ab4d1f3bc1/40001_2024_2232_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f6c/11724497/ca6b1e40ac30/40001_2024_2232_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f6c/11724497/d2ca77a203f2/40001_2024_2232_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f6c/11724497/044a5ae53501/40001_2024_2232_Fig6_HTML.jpg

相似文献

1
SUGT1 is a prognostic biomarker and is associated with immune infiltrates in ovarian cancer.SUGT1是一种预后生物标志物,与卵巢癌中的免疫浸润相关。
Eur J Med Res. 2025 Jan 10;30(1):21. doi: 10.1186/s40001-024-02232-5.
2
SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma.SLAMF7 预测浆液性卵巢癌的预后,并与免疫浸润相关。
J Gynecol Oncol. 2024 Nov;35(6):e79. doi: 10.3802/jgo.2024.35.e79. Epub 2024 Mar 29.
3
Investigating PPT2's role in ovarian cancer prognosis and immunotherapy outcomes.探讨 PPT2 在卵巢癌预后和免疫治疗结果中的作用。
J Ovarian Res. 2024 Oct 11;17(1):198. doi: 10.1186/s13048-024-01527-9.
4
REEP3 is a potential diagnostic and prognostic biomarker correlated with immune infiltration in pancreatic cancer.REEP3 是一种与胰腺癌免疫浸润相关的潜在诊断和预后生物标志物。
Sci Rep. 2024 Jun 15;14(1):13834. doi: 10.1038/s41598-024-64720-2.
5
Identification of MEG8/miR-378d/SOBP axis as a novel regulatory network and associated with immune infiltrates in ovarian carcinoma by integrated bioinformatics analysis.通过综合生物信息学分析鉴定 MEG8/miR-378d/SOBP 轴作为一个新的调控网络,并与卵巢癌中的免疫浸润相关。
Cancer Med. 2021 Apr;10(8):2924-2939. doi: 10.1002/cam4.3854. Epub 2021 Mar 19.
6
Col1A1 as a new decoder of clinical features and immune microenvironment in ovarian cancer.胶原蛋白1A1作为卵巢癌临床特征和免疫微环境的新解码因子。
Front Immunol. 2025 Jan 8;15:1496090. doi: 10.3389/fimmu.2024.1496090. eCollection 2024.
7
A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.一种经TCGA验证的卵巢癌程序性细胞死亡相关特征。
BMC Cancer. 2024 Apr 23;24(1):515. doi: 10.1186/s12885-024-12245-2.
8
Integrating Single-Cell and Bulk RNA Sequencing Data to Explore Sphingolipid Metabolism Molecular Signatures in Ovarian Cancer Prognosis: an Original Study.整合单细胞和批量RNA测序数据以探索鞘脂代谢分子特征在卵巢癌预后中的作用:一项原创研究
Int J Med Sci. 2025 Mar 24;22(8):1958-1977. doi: 10.7150/ijms.107391. eCollection 2025.
9
Identification and validation of a prognostic model based on immune-related genes in ovarian carcinoma.基于免疫相关基因的卵巢癌预后模型的鉴定和验证。
PeerJ. 2024 Oct 31;12:e18235. doi: 10.7717/peerj.18235. eCollection 2024.
10
Development and evaluation of an ovarian cancer prognostic model based on adaptive immune-related genes.基于适应性免疫相关基因的卵巢癌预后模型的构建与评估
Medicine (Baltimore). 2025 Apr 4;104(14):e42030. doi: 10.1097/MD.0000000000042030.

本文引用的文献

1
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
2
Molecular Biomarkers for the Early Detection of Ovarian Cancer.用于卵巢癌早期检测的分子生物标志物。
Int J Mol Sci. 2022 Oct 10;23(19):12041. doi: 10.3390/ijms231912041.
3
Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition.巨噬细胞线粒体分裂可改善治疗性抗体诱导的癌细胞吞噬作用,并因谷氨酰胺竞争而受损。
Nat Cancer. 2022 Apr;3(4):453-470. doi: 10.1038/s43018-022-00354-5. Epub 2022 Apr 28.
4
Fatty Acid Metabolism in Ovarian Cancer: Therapeutic Implications.脂肪酸代谢与卵巢癌:治疗学意义。
Int J Mol Sci. 2022 Feb 16;23(4):2170. doi: 10.3390/ijms23042170.
5
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors.卵巢癌除了 PARP 抑制剂以外的组织学特异性靶向治疗的新兴分子改变。
Cancer Treat Rev. 2021 Dec;101:102298. doi: 10.1016/j.ctrv.2021.102298. Epub 2021 Sep 29.
6
Curcumin Nanoparticle Enhances the Anticancer Effect of Cisplatin by Inhibiting PI3K/AKT and JAK/STAT3 Pathway in Rat Ovarian Carcinoma Induced by DMBA.姜黄素纳米颗粒通过抑制二甲基苯并蒽诱导的大鼠卵巢癌中的PI3K/AKT和JAK/STAT3信号通路增强顺铂的抗癌作用。
Front Pharmacol. 2021 Jan 18;11:603235. doi: 10.3389/fphar.2020.603235. eCollection 2020.
7
Correlation analysis and clinical significance of CA125, HE4, DDI, and FDP in type II epithelial ovarian cancer.CA125、HE4、DDI和FDP在II型上皮性卵巢癌中的相关性分析及临床意义
Medicine (Baltimore). 2020 Dec 4;99(49):e23329. doi: 10.1097/MD.0000000000023329.
8
Dendritic cell subsets and locations.树突状细胞亚群和位置。
Int Rev Cell Mol Biol. 2019;348:1-68. doi: 10.1016/bs.ircmb.2019.07.004. Epub 2019 Sep 3.
9
Phagocytosis checkpoints as new targets for cancer immunotherapy.吞噬作用检查点作为癌症免疫治疗的新靶点。
Nat Rev Cancer. 2019 Oct;19(10):568-586. doi: 10.1038/s41568-019-0183-z. Epub 2019 Aug 28.
10
Epithelial ovarian cancer: Evolution of management in the era of precision medicine.上皮性卵巢癌:精准医学时代的治疗进展。
CA Cancer J Clin. 2019 Jul;69(4):280-304. doi: 10.3322/caac.21559. Epub 2019 May 17.